MAP3K8 antibody (C-Term)
Quick Overview for MAP3K8 antibody (C-Term) (ABIN360360)
Target
See all MAP3K8 AntibodiesReactivity
Host
Clonality
Conjugate
Application
-
-
Binding Specificity
- C-Term
-
Specificity
- This antibody reacts to COT (MAP3K8/MEKK8).
-
Purification
- Protein G column, eluted with high and low pH buffers and neutralized immediately, followed by dialysis against PBS
-
Immunogen
- This antibody is generated from rabbits immunized with a KLH conjugated synthetic peptide selected from the C-terminal region of human COT.
-
Isotype
- Ig Fraction
-
-
-
-
Application Notes
-
ELISA: 1/1,000. Western blotting: 1/100 - 1/500. Immunohistochemistry: 1/50 - 1/100.
Other applications not tested.
Optimal dilutions are dependent on conditions and should be determined by the user. -
Restrictions
- For Research Use only
-
-
-
Format
- Liquid
-
Concentration
- 0.25 mg/mL
-
Buffer
- PBS with 0.09 % (W/V) sodium azide
-
Preservative
- Sodium azide
-
Precaution of Use
- This product contains sodium azide: a POISONOUS AND HAZARDOUS SUBSTANCE which should be handled by trained staff only.
-
Handling Advice
- Avoid repeated freezing and thawing.
-
Storage
- 4 °C/-20 °C
-
Storage Comment
- Store the antibody undiluted at 2-8 °C for one month or (in aliquots) at-20 °C for longer.
-
-
- MAP3K8 (Mitogen-Activated Protein Kinase Kinase Kinase 8 (MAP3K8))
-
Alternative Name
- MAP3K8 / TPL-2
-
Background
- COT, a member of the MAPKKK subfamily of Ser/Thr protein kinases, is able to activate NF-kappa-B 1 by stimulating proteasome-mediated proteolysis of NF-kappa-B 1/p105. It plays a role in the cell cycle. The longer form of cot has some transforming activity, although it is much weaker than the activated cot oncoprotein. This cytoplasmic protein is expressed in several normal tissues and human tumor-derived cell lines. The 58 kDa form is activated specifically during the S and G2/M phases of the cell cycle. The longer form undergoes phosphorylation on Ser residues mainly, and the shorter form on both Ser and Thr residues.Synonyms: COT, COT proto-oncogene serine/threonine-protein kinase, Cancer Osaka thyroid oncogene, ESTF, MAPK, Mitogen-activated protein kinase kinase kinase 8, Tumor progression locus 2, Tumor progression locus 2
-
Gene ID
- 1326, 9606
-
UniProt
- P41279
-
Pathways
- PI3K-Akt Signaling, TCR Signaling
Target
-